Synopsis
0
EU WC
0
KDMF
0
VMF
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
Click Us!
BR, ASMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
REF. STANDARDS & IMPURITIES
USP
ABOUT THIS PAGE
A Deferoxamine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Deferoxamine, including repackagers and relabelers. The FDA regulates Deferoxamine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Deferoxamine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Deferoxamine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Deferoxamine supplier is an individual or a company that provides Deferoxamine active pharmaceutical ingredient (API) or Deferoxamine finished formulations upon request. The Deferoxamine suppliers may include Deferoxamine API manufacturers, exporters, distributors and traders.
click here to find a list of Deferoxamine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Deferoxamine DMF (Drug Master File) is a document detailing the whole manufacturing process of Deferoxamine active pharmaceutical ingredient (API) in detail. Different forms of Deferoxamine DMFs exist exist since differing nations have different regulations, such as Deferoxamine USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Deferoxamine DMF submitted to regulatory agencies in the US is known as a USDMF. Deferoxamine USDMF includes data on Deferoxamine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Deferoxamine USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Deferoxamine suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Deferoxamine Drug Master File in Japan (Deferoxamine JDMF) empowers Deferoxamine API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Deferoxamine JDMF during the approval evaluation for pharmaceutical products. At the time of Deferoxamine JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Deferoxamine suppliers with JDMF on PharmaCompass.
A Deferoxamine CEP of the European Pharmacopoeia monograph is often referred to as a Deferoxamine Certificate of Suitability (COS). The purpose of a Deferoxamine CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Deferoxamine EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Deferoxamine to their clients by showing that a Deferoxamine CEP has been issued for it. The manufacturer submits a Deferoxamine CEP (COS) as part of the market authorization procedure, and it takes on the role of a Deferoxamine CEP holder for the record. Additionally, the data presented in the Deferoxamine CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Deferoxamine DMF.
A Deferoxamine CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Deferoxamine CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Deferoxamine suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Deferoxamine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Deferoxamine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Deferoxamine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Deferoxamine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Deferoxamine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Deferoxamine suppliers with NDC on PharmaCompass.
Deferoxamine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Deferoxamine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Deferoxamine GMP manufacturer or Deferoxamine GMP API supplier for your needs.
A Deferoxamine CoA (Certificate of Analysis) is a formal document that attests to Deferoxamine's compliance with Deferoxamine specifications and serves as a tool for batch-level quality control.
Deferoxamine CoA mostly includes findings from lab analyses of a specific batch. For each Deferoxamine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Deferoxamine may be tested according to a variety of international standards, such as European Pharmacopoeia (Deferoxamine EP), Deferoxamine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Deferoxamine USP).
LOOKING FOR A SUPPLIER?
